EUVIMEDEUVIMED entdecken
Crossref

Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab

Takayuki Nakayama, Hideki Takeshita, Makoto Kagawa, Satoshi Washino, Suguru Shirotake, Yuji Miura, Yoji Hyodo, Keita Izumi, Masaharu Inoue, Yoh Matsuoka, Tomoaki Miyagawa, Masafumi Oyama und 2 weitere

International Journal of Clinical Oncology · 2024-10 · 29 (10) · 1528-1537

DOI: 10.1007/s10147-024-02593-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 24.07.2024. Verfasst von Takayuki Nakayama und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan. Hauptthemen laut MEDLINE: Ipilimumab, Carcinoma, Renal Cell, Nivolumab, Kidney Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Saitama Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: A useful biomarker for the efficacy of immune checkpoint inhibitors (ICIs) in advanced renal cell carcinoma (RCC) has not yet been established. This study aims to investigate whether inflammatory markers are associated with the efficacy of nivolumab plus ipilimumab therapy before and during treatment. METHODS: Data from patients with advanced clear cell RCC who received a combination treatment of nivolumab plus ipilimumab were retrospectively analyzed. The neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) levels were assessed at baseline and 3, 6, and 9 weeks after treatment initiation. The correlation between these inflammatory markers and the patient's prognosis was investigated. RESULTS: Eighty-four patients were identified. The multivariate analysis identified NLR at week 3, CRP at week 6, and NLR and CRP at week 9 as the consistent predictor associated with poor overall survival (OS) at each time point. The survival analysis and receiver operating characteristic (ROC) curve analysis revealed that an NLR of ≥ 2.4 at week 3, CRP of ≥ 1.4 mg/dL at week 6, and NLR of ≥ 4.8 and CRP of ≥ 1.0 mg/dL at week 9 were associated with worse OS (hazard ratios (HR) = 5.70, P = 0.008, HR = 3.23, P = 0.004, HR = 7.38, P < 0.001 and HR = 3.55, P = 0.002). CONCLUSIONS: Both NLR and CRP were considered useful biomarkers for understanding the prognosis during nivolumab plus ipilimumab therapy. Furthermore, an NLR of ≥ 4.8 and CRP of ≥ 1.0 mg/dL at week 9 are helpful in reconsidering treatment continuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IpilimumabCarcinoma, Renal CellNivolumabKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsC-Reactive ProteinNeutrophilsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesPrognosisAdultAged, 80 and overBiomarkers, TumorLymphocytes

Stichwörter der Autor:innen

AdvancedC-reactive proteinClear cell renal cell carcinomaImmune checkpoint inhibitorInflammatory markerPrognosis

Substanzen

IpilimumabNivolumabC-Reactive ProteinBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan.
  • Musashinno Study Group, Saitama, Japan.
  • Department of Urology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan. takeuro@saitama-med.ac.jp.
  • Musashinno Study Group, Saitama, Japan. takeuro@saitama-med.ac.jp.
  • Department of Urology, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama, 330-8503, Japan.
  • Department of Uro-Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan.

Förderung

  • Saitama Medical University

Zitieren

APA

Nakayama, T., Takeshita, H., Kagawa, M., Washino, S., Shirotake, S., Miura, Y., Hyodo, Y., Izumi, K., Inoue, M., Matsuoka, Y., Miyagawa, T., Oyama, M., Saito, K., & Kawakami, S. (2024). Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab. International Journal of Clinical Oncology, 29(10), 1528-1537. https://doi.org/10.1007/s10147-024-02593-1

Vancouver

Nakayama T, Takeshita H, Kagawa M, Washino S, Shirotake S, Miura Y, et al. Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab. International Journal of Clinical Oncology. 2024;29(10):1528-1537. doi:10.1007/s10147-024-02593-1

BibTeX
@article{Nakayama2024,
  author = {Nakayama, Takayuki and Takeshita, Hideki and Kagawa, Makoto and Washino, Satoshi and Shirotake, Suguru and Miura, Yuji and Hyodo, Yoji and Izumi, Keita and Inoue, Masaharu and Matsuoka, Yoh and Miyagawa, Tomoaki and Oyama, Masafumi and Saito, Kazutaka and Kawakami, Satoru},
  title = {Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  volume = {29},
  number = {10},
  pages = {1528--1537},
  doi = {10.1007/s10147-024-02593-1}
}
Kostenlos starten →